2.225USD-1.55%Mkt Cap: 398.58M USDP/E: —Last update: 2026-05-26
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candida…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap398.58M USD
Enterprise Value336.22M USD
Revenue (TTM)109.16M USD
Gross Profit13.50M USD
Net Income (TTM)-9.58M USD
Revenue/Share1.261 USD
Last Price2.225 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees78
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.39
PEG—
EV/EBITDA-173.40
EV/Revenue3.08
P/S3.75
P/B1.25
EPS (TTM)-1.14
EPS (Forward)-0.52
52W Range
0.435069% of range3.040
52W High3.040 USD
52W Low0.4350 USD
Profitability
Gross Margin12.36%
Oper. Margin-13.78%
EBITDA Margin-1.78%
Profit Margin-8.78%
ROE-6.03%
ROA-4.28%
Growth
Revenue Growth-100.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-103.88M USD
CapEx (TTM)848.00K USD
FCF Margin-89.05%
FCF Yield-24.39%
Net Debt-73.55M USD
Net Debt/EBITDA37.93
Balance Sheet
Debt/Equity0.27
Current Ratio5.97
Quick Ratio5.82
Book Value/Sh1.816 USD
Cash/Share0.6520 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Target (Mean)3.667 USD
Target Range2.000 USD – 5.000 USD
# Analysts3
Ownership
Shares Out.180.35M
Float97.82M
Insiders12.08%
Institutions65.59%
Short Interest
Short Ratio10.7d
Short % Float6.73%
Short % Out.6.68%
Shares Short12.05M
Short (prev mo.)10.29M
Technical
SMA 502.290 (-2.8%)
SMA 2001.349 (+64.9%)
Beta1.56
S&P 52W Chg28.31%
Avg Vol (30d)824.58K
Avg Vol (10d)742.41K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—